Global Influenzavirus B Infection Drug Market Research Report 2024

Report ID: 1978129 | Published Date: Jan 2025 | No. of Page: 117 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Influenzavirus B Infection Drug Market Overview
    1.1 Product Overview and Scope of Influenzavirus B Infection Drug
    1.2 Influenzavirus B Infection Drug Segment by Type
        1.2.1 Global Influenzavirus B Infection Drug Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 APP-309
        1.2.3 CF-403
        1.2.4 GC-3106A
        1.2.5 KIN-1400
        1.2.6 Others
    1.3 Influenzavirus B Infection Drug Segment by Application
        1.3.1 Global Influenzavirus B Infection Drug Sales Comparison by Application: (2022-2028)
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 Global Influenzavirus B Infection Drug Market Size Estimates and Forecasts
        1.4.1 Global Influenzavirus B Infection Drug Revenue 2017-2028
        1.4.2 Global Influenzavirus B Infection Drug Sales 2017-2028
        1.4.3 Influenzavirus B Infection Drug Market Size by Region: 2017 Versus 2021 Versus 2028
2 Influenzavirus B Infection Drug Market Competition by Manufacturers
    2.1 Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Influenzavirus B Infection Drug Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Influenzavirus B Infection Drug Manufacturing Sites, Area Served, Product Type
    2.5 Influenzavirus B Infection Drug Market Competitive Situation and Trends
        2.5.1 Influenzavirus B Infection Drug Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Influenzavirus B Infection Drug Players Market Share by Revenue
        2.5.3 Global Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Influenzavirus B Infection Drug Retrospective Market Scenario by Region
    3.1 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Influenzavirus B Infection Drug Market Facts & Figures by Country
        3.3.1 North America Influenzavirus B Infection Drug Sales by Country
        3.3.2 North America Influenzavirus B Infection Drug Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Influenzavirus B Infection Drug Market Facts & Figures by Country
        3.4.1 Europe Influenzavirus B Infection Drug Sales by Country
        3.4.2 Europe Influenzavirus B Infection Drug Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Region
        3.5.1 Asia Pacific Influenzavirus B Infection Drug Sales by Region
        3.5.2 Asia Pacific Influenzavirus B Infection Drug Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Influenzavirus B Infection Drug Market Facts & Figures by Country
        3.6.1 Latin America Influenzavirus B Infection Drug Sales by Country
        3.6.2 Latin America Influenzavirus B Infection Drug Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Country
        3.7.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Country
        3.7.2 Middle East and Africa Influenzavirus B Infection Drug Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Influenzavirus B Infection Drug Historic Market Analysis by Type
    4.1 Global Influenzavirus B Infection Drug Sales Market Share by Type (2017-2022)
    4.2 Global Influenzavirus B Infection Drug Revenue Market Share by Type (2017-2022)
    4.3 Global Influenzavirus B Infection Drug Price by Type (2017-2022)
5 Global Influenzavirus B Infection Drug Historic Market Analysis by Application
    5.1 Global Influenzavirus B Infection Drug Sales Market Share by Application (2017-2022)
    5.2 Global Influenzavirus B Infection Drug Revenue Market Share by Application (2017-2022)
    5.3 Global Influenzavirus B Infection Drug Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 AbbVie Inc
        6.1.1 AbbVie Inc Corporation Information
        6.1.2 AbbVie Inc Description and Business Overview
        6.1.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
        6.1.5 AbbVie Inc Recent Developments/Updates
    6.2 Adimmune Corp
        6.2.1 Adimmune Corp Corporation Information
        6.2.2 Adimmune Corp Description and Business Overview
        6.2.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
        6.2.5 Adimmune Corp Recent Developments/Updates
    6.3 Altravax Inc
        6.3.1 Altravax Inc Corporation Information
        6.3.2 Altravax Inc Description and Business Overview
        6.3.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
        6.3.5 Altravax Inc Recent Developments/Updates
    6.4 Amarillo Biosciences Inc
        6.4.1 Amarillo Biosciences Inc Corporation Information
        6.4.2 Amarillo Biosciences Inc Description and Business Overview
        6.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
        6.4.5 Amarillo Biosciences Inc Recent Developments/Updates
    6.5 Aphios Corp
        6.5.1 Aphios Corp Corporation Information
        6.5.2 Aphios Corp Description and Business Overview
        6.5.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
        6.5.5 Aphios Corp Recent Developments/Updates
    6.6 BioCryst Pharmaceuticals Inc
        6.6.1 BioCryst Pharmaceuticals Inc Corporation Information
        6.6.2 BioCryst Pharmaceuticals Inc Description and Business Overview
        6.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
        6.6.5 BioCryst Pharmaceuticals Inc Recent Developments/Updates
    6.7 Cadila Healthcare Ltd
        6.6.1 Cadila Healthcare Ltd Corporation Information
        6.6.2 Cadila Healthcare Ltd Description and Business Overview
        6.6.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
        6.7.5 Cadila Healthcare Ltd Recent Developments/Updates
    6.8 ContraFect Corp
        6.8.1 ContraFect Corp Corporation Information
        6.8.2 ContraFect Corp Description and Business Overview
        6.8.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
        6.8.5 ContraFect Corp Recent Developments/Updates
    6.9 Daiichi Sankyo Company Ltd
        6.9.1 Daiichi Sankyo Company Ltd Corporation Information
        6.9.2 Daiichi Sankyo Company Ltd Description and Business Overview
        6.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
        6.9.5 Daiichi Sankyo Company Ltd Recent Developments/Updates
    6.10 Fujifilm Holdings Corporation
        6.10.1 Fujifilm Holdings Corporation Corporation Information
        6.10.2 Fujifilm Holdings Corporation Description and Business Overview
        6.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
        6.10.5 Fujifilm Holdings Corporation Recent Developments/Updates
    6.11 GlaxoSmithKline Plc
        6.11.1 GlaxoSmithKline Plc Corporation Information
        6.11.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Description and Business Overview
        6.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
        6.11.5 GlaxoSmithKline Plc Recent Developments/Updates
    6.12 Green Cross Corp
        6.12.1 Green Cross Corp Corporation Information
        6.12.2 Green Cross Corp Influenzavirus B Infection Drug Description and Business Overview
        6.12.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
        6.12.5 Green Cross Corp Recent Developments/Updates
    6.13 Inovio Pharmaceuticals Inc
        6.13.1 Inovio Pharmaceuticals Inc Corporation Information
        6.13.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Description and Business Overview
        6.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
        6.13.5 Inovio Pharmaceuticals Inc Recent Developments/Updates
    6.14 Kineta Inc
        6.14.1 Kineta Inc Corporation Information
        6.14.2 Kineta Inc Influenzavirus B Infection Drug Description and Business Overview
        6.14.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.14.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
        6.14.5 Kineta Inc Recent Developments/Updates
    6.15 Medicago Inc
        6.15.1 Medicago Inc Corporation Information
        6.15.2 Medicago Inc Influenzavirus B Infection Drug Description and Business Overview
        6.15.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.15.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
        6.15.5 Medicago Inc Recent Developments/Updates
    6.16 MedImmune LLC
        6.16.1 MedImmune LLC Corporation Information
        6.16.2 MedImmune LLC Influenzavirus B Infection Drug Description and Business Overview
        6.16.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.16.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
        6.16.5 MedImmune LLC Recent Developments/Updates
    6.17 Mucosis BV
        6.17.1 Mucosis BV Corporation Information
        6.17.2 Mucosis BV Influenzavirus B Infection Drug Description and Business Overview
        6.17.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.17.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
        6.17.5 Mucosis BV Recent Developments/Updates
    6.18 Novavax Inc
        6.18.1 Novavax Inc Corporation Information
        6.18.2 Novavax Inc Influenzavirus B Infection Drug Description and Business Overview
        6.18.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.18.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
        6.18.5 Novavax Inc Recent Developments/Updates
    6.19 Park Active Molecules
        6.19.1 Park Active Molecules Corporation Information
        6.19.2 Park Active Molecules Influenzavirus B Infection Drug Description and Business Overview
        6.19.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.19.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
        6.19.5 Park Active Molecules Recent Developments/Updates
    6.20 Romark Laboratories LC
        6.20.1 Romark Laboratories LC Corporation Information
        6.20.2 Romark Laboratories LC Influenzavirus B Infection Drug Description and Business Overview
        6.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.20.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
        6.20.5 Romark Laboratories LC Recent Developments/Updates
    6.21 Sanofi
        6.21.1 Sanofi Corporation Information
        6.21.2 Sanofi Influenzavirus B Infection Drug Description and Business Overview
        6.21.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.21.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
        6.21.5 Sanofi Recent Developments/Updates
    6.22 Sanofi Pasteur SA
        6.22.1 Sanofi Pasteur SA Corporation Information
        6.22.2 Sanofi Pasteur SA Influenzavirus B Infection Drug Description and Business Overview
        6.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.22.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
        6.22.5 Sanofi Pasteur SA Recent Developments/Updates
    6.23 Shionogi & Co Ltd
        6.23.1 Shionogi & Co Ltd Corporation Information
        6.23.2 Shionogi & Co Ltd Influenzavirus B Infection Drug Description and Business Overview
        6.23.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.23.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
        6.23.5 Shionogi & Co Ltd Recent Developments/Updates
    6.24 SK Chemicals Co Ltd
        6.24.1 SK Chemicals Co Ltd Corporation Information
        6.24.2 SK Chemicals Co Ltd Influenzavirus B Infection Drug Description and Business Overview
        6.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.24.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
        6.24.5 SK Chemicals Co Ltd Recent Developments/Updates
    6.25 TSRL Inc
        6.25.1 TSRL Inc Corporation Information
        6.25.2 TSRL Inc Influenzavirus B Infection Drug Description and Business Overview
        6.25.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.25.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
        6.25.5 TSRL Inc Recent Developments/Updates
    6.26 Vaxart Inc
        6.26.1 Vaxart Inc Corporation Information
        6.26.2 Vaxart Inc Influenzavirus B Infection Drug Description and Business Overview
        6.26.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.26.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
        6.26.5 Vaxart Inc Recent Developments/Updates
    6.27 Vectura Group Plc
        6.27.1 Vectura Group Plc Corporation Information
        6.27.2 Vectura Group Plc Influenzavirus B Infection Drug Description and Business Overview
        6.27.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2017-2022)
        6.27.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
        6.27.5 Vectura Group Plc Recent Developments/Updates
7 Influenzavirus B Infection Drug Manufacturing Cost Analysis
    7.1 Influenzavirus B Infection Drug Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Influenzavirus B Infection Drug
    7.4 Influenzavirus B Infection Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Influenzavirus B Infection Drug Distributors List
    8.3 Influenzavirus B Infection Drug Customers
9 Influenzavirus B Infection Drug Market Dynamics
    9.1 Influenzavirus B Infection Drug Industry Trends
    9.2 Influenzavirus B Infection Drug Market Drivers
    9.3 Influenzavirus B Infection Drug Market Challenges
    9.4 Influenzavirus B Infection Drug Market Restraints
10 Global Market Forecast
    10.1 Influenzavirus B Infection Drug Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Influenzavirus B Infection Drug by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Influenzavirus B Infection Drug by Type (2023-2028)
    10.2 Influenzavirus B Infection Drug Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Influenzavirus B Infection Drug by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Influenzavirus B Infection Drug by Application (2023-2028)
    10.3 Influenzavirus B Infection Drug Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Influenzavirus B Infection Drug by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Influenzavirus B Infection Drug by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Influenzavirus B Infection Drug Sales Growth Rate Comparison by Type (2022-2028) & (K Pcs) & (US$ Million)
    Table 2. Global Influenzavirus B Infection Drug Sales Growth Rate Comparison by Application (2022-2028) & (K Pcs) & (US$ Million)
    Table 3. Global Influenzavirus B Infection Drug Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Influenzavirus B Infection Drug Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Influenzavirus B Infection Drug Sales (K Pcs) of Key Manufacturers (2017-2022)
    Table 6. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Influenzavirus B Infection Drug Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Influenzavirus B Infection Drug Average Price (USD/Pcs) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Influenzavirus B Infection Drug Manufacturing Sites and Area Served
    Table 11. Manufacturers Influenzavirus B Infection Drug Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenzavirus B Infection Drug as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Influenzavirus B Infection Drug Sales by Region (2017-2022) & (K Pcs)
    Table 16. Global Influenzavirus B Infection Drug Sales Market Share by Region (2017-2022)
    Table 17. Global Influenzavirus B Infection Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2017-2022)
    Table 19. North America Influenzavirus B Infection Drug Sales by Country (2017-2022) & (K Pcs)
    Table 20. North America Influenzavirus B Infection Drug Sales Market Share by Country (2017-2022)
    Table 21. North America Influenzavirus B Infection Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Influenzavirus B Infection Drug Revenue Market Share by Country (2017-2022)
    Table 23. Europe Influenzavirus B Infection Drug Sales by Country (2017-2022) & (K Pcs)
    Table 24. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2017-2022)
    Table 25. Europe Influenzavirus B Infection Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Influenzavirus B Infection Drug Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Influenzavirus B Infection Drug Sales by Region (2017-2022) & (K Pcs)
    Table 28. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Influenzavirus B Infection Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Influenzavirus B Infection Drug Sales by Country (2017-2022) & (K Pcs)
    Table 32. Latin America Influenzavirus B Infection Drug Sales Market Share by Country (2017-2022)
    Table 33. Latin America Influenzavirus B Infection Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2017-2022) & (K Pcs)
    Table 36. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country (2017-2022)
    Table 39. Global Influenzavirus B Infection Drug Sales by Type (2017-2022) & (K Pcs)
    Table 40. Global Influenzavirus B Infection Drug Sales Market Share by Type (2017-2022)
    Table 41. Global Influenzavirus B Infection Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Influenzavirus B Infection Drug Revenue Share by Type (2017-2022)
    Table 43. Global Influenzavirus B Infection Drug Price by Type (2017-2022) & (USD/Pcs)
    Table 44. Global Influenzavirus B Infection Drug Sales (K Pcs) by Application (2017-2022)
    Table 45. Global Influenzavirus B Infection Drug Sales Market Share by Application (2017-2022)
    Table 46. Global Influenzavirus B Infection Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Influenzavirus B Infection Drug Revenue Share by Application (2017-2022)
    Table 48. Global Influenzavirus B Infection Drug Price by Application (2017-2022) & (USD/Pcs)
    Table 49. AbbVie Inc Corporation Information
    Table 50. AbbVie Inc Description and Business Overview
    Table 51. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 52. AbbVie Inc Influenzavirus B Infection Drug Product
    Table 53. AbbVie Inc Recent Developments/Updates
    Table 54. Adimmune Corp Corporation Information
    Table 55. Adimmune Corp Description and Business Overview
    Table 56. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 57. Adimmune Corp Influenzavirus B Infection Drug Product
    Table 58. Adimmune Corp Recent Developments/Updates
    Table 59. Altravax Inc Corporation Information
    Table 60. Altravax Inc Description and Business Overview
    Table 61. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 62. Altravax Inc Influenzavirus B Infection Drug Product
    Table 63. Altravax Inc Recent Developments/Updates
    Table 64. Amarillo Biosciences Inc Corporation Information
    Table 65. Amarillo Biosciences Inc Description and Business Overview
    Table 66. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 67. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product
    Table 68. Amarillo Biosciences Inc Recent Developments/Updates
    Table 69. Aphios Corp Corporation Information
    Table 70. Aphios Corp Description and Business Overview
    Table 71. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 72. Aphios Corp Influenzavirus B Infection Drug Product
    Table 73. Aphios Corp Recent Developments/Updates
    Table 74. BioCryst Pharmaceuticals Inc Corporation Information
    Table 75. BioCryst Pharmaceuticals Inc Description and Business Overview
    Table 76. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 77. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product
    Table 78. BioCryst Pharmaceuticals Inc Recent Developments/Updates
    Table 79. Cadila Healthcare Ltd Corporation Information
    Table 80. Cadila Healthcare Ltd Description and Business Overview
    Table 81. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 82. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product
    Table 83. Cadila Healthcare Ltd Recent Developments/Updates
    Table 84. ContraFect Corp Corporation Information
    Table 85. ContraFect Corp Description and Business Overview
    Table 86. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 87. ContraFect Corp Influenzavirus B Infection Drug Product
    Table 88. ContraFect Corp Recent Developments/Updates
    Table 89. Daiichi Sankyo Company Ltd Corporation Information
    Table 90. Daiichi Sankyo Company Ltd Description and Business Overview
    Table 91. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 92. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product
    Table 93. Daiichi Sankyo Company Ltd Recent Developments/Updates
    Table 94. Fujifilm Holdings Corporation Corporation Information
    Table 95. Fujifilm Holdings Corporation Description and Business Overview
    Table 96. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 97. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product
    Table 98. Fujifilm Holdings Corporation Recent Developments/Updates
    Table 99. GlaxoSmithKline Plc Corporation Information
    Table 100. GlaxoSmithKline Plc Description and Business Overview
    Table 101. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 102. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product
    Table 103. GlaxoSmithKline Plc Recent Developments/Updates
    Table 104. Green Cross Corp Corporation Information
    Table 105. Green Cross Corp Description and Business Overview
    Table 106. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 107. Green Cross Corp Influenzavirus B Infection Drug Product
    Table 108. Green Cross Corp Recent Developments/Updates
    Table 109. Inovio Pharmaceuticals Inc Corporation Information
    Table 110. Inovio Pharmaceuticals Inc Description and Business Overview
    Table 111. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 112. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product
    Table 113. Inovio Pharmaceuticals Inc Recent Developments/Updates
    Table 114. Kineta Inc Corporation Information
    Table 115. Kineta Inc Description and Business Overview
    Table 116. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 117. Kineta Inc Influenzavirus B Infection Drug Product
    Table 118. Kineta Inc Recent Developments/Updates
    Table 119. Medicago Inc Corporation Information
    Table 120. Medicago Inc Description and Business Overview
    Table 121. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 122. Medicago Inc Influenzavirus B Infection Drug Product
    Table 123. Medicago Inc Recent Developments/Updates
    Table 124. MedImmune LLC Corporation Information
    Table 125. MedImmune LLC Description and Business Overview
    Table 126. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 127. MedImmune LLC Influenzavirus B Infection Drug Product
    Table 128. MedImmune LLC Recent Developments/Updates
    Table 129. Mucosis BV Corporation Information
    Table 130. Mucosis BV Description and Business Overview
    Table 131. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 132. Mucosis BV Influenzavirus B Infection Drug Product
    Table 133. Mucosis BV Recent Developments/Updates
    Table 134. Novavax Inc Corporation Information
    Table 135. Novavax Inc Description and Business Overview
    Table 136. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 137. Novavax Inc Influenzavirus B Infection Drug Product
    Table 138. Novavax Inc Recent Developments/Updates
    Table 139. Park Active Molecules Corporation Information
    Table 140. Park Active Molecules Description and Business Overview
    Table 141. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 142. Park Active Molecules Influenzavirus B Infection Drug Product
    Table 143. Park Active Molecules Recent Developments/Updates
    Table 144. Romark Laboratories LC Corporation Information
    Table 145. Romark Laboratories LC Description and Business Overview
    Table 146. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 147. Romark Laboratories LC Influenzavirus B Infection Drug Product
    Table 148. Romark Laboratories LC Recent Developments/Updates
    Table 149. Sanofi Corporation Information
    Table 150. Sanofi Description and Business Overview
    Table 151. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 152. Sanofi Influenzavirus B Infection Drug Product
    Table 153. Sanofi Recent Developments/Updates
    Table 154. Sanofi Pasteur SA Corporation Information
    Table 155. Sanofi Pasteur SA Description and Business Overview
    Table 156. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 157. Sanofi Pasteur SA Influenzavirus B Infection Drug Product
    Table 158. Sanofi Pasteur SA Recent Developments/Updates
    Table 159. Shionogi & Co Ltd Corporation Information
    Table 160. Shionogi & Co Ltd Description and Business Overview
    Table 161. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 162. Shionogi & Co Ltd Influenzavirus B Infection Drug Product
    Table 163. Shionogi & Co Ltd Recent Developments/Updates
    Table 164. SK Chemicals Co Ltd Corporation Information
    Table 165. SK Chemicals Co Ltd Description and Business Overview
    Table 166. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 167. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product
    Table 168. SK Chemicals Co Ltd Recent Developments/Updates
    Table 169. TSRL Inc Corporation Information
    Table 170. TSRL Inc Description and Business Overview
    Table 171. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 172. TSRL Inc Influenzavirus B Infection Drug Product
    Table 173. TSRL Inc Recent Developments/Updates
    Table 174. Vaxart Inc Corporation Information
    Table 175. Vaxart Inc Description and Business Overview
    Table 176. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 177. Vaxart Inc Influenzavirus B Infection Drug Product
    Table 178. Vaxart Inc Recent Developments/Updates
    Table 179. Vectura Group Plc Corporation Information
    Table 180. Vectura Group Plc Description and Business Overview
    Table 181. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 182. Vectura Group Plc Influenzavirus B Infection Drug Product
    Table 183. Vectura Group Plc Recent Developments/Updates
    Table 184. Production Base and Market Concentration Rate of Raw Material
    Table 185. Key Suppliers of Raw Materials
    Table 186. Influenzavirus B Infection Drug Distributors List
    Table 187. Influenzavirus B Infection Drug Customers List
    Table 188. Influenzavirus B Infection Drug Market Trends
    Table 189. Influenzavirus B Infection Drug Market Drivers
    Table 190. Influenzavirus B Infection Drug Market Challenges
    Table 191. Influenzavirus B Infection Drug Market Restraints
    Table 192. Global Influenzavirus B Infection Drug Sales Forecast by Type (2023-2028) & (K Pcs)
    Table 193. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Type (2023-2028)
    Table 194. Global Influenzavirus B Infection Drug Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 195. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Type (2023-2028)
    Table 196. Global Influenzavirus B Infection Drug Sales Forecast by Application (2023-2028) & (K Pcs)
    Table 197. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Application (2023-2028)
    Table 198. Global Influenzavirus B Infection Drug Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 199. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Application (2023-2028)
    Table 200. Global Influenzavirus B Infection Drug Sales Forecast by Region (2023-2028) & (K Pcs)
    Table 201. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Region (2023-2028)
    Table 202. Global Influenzavirus B Infection Drug Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 203. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Region (2023-2028)
    Table 204. Research Programs/Design for This Report
    Table 205. Key Data Information from Secondary Sources
    Table 206. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Influenzavirus B Infection Drug
    Figure 2. Global Influenzavirus B Infection Drug Market Share by Type in 2021 & 2028
    Figure 3. APP-309 Product Picture
    Figure 4. CF-403 Product Picture
    Figure 5. GC-3106A Product Picture
    Figure 6. KIN-1400 Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global Influenzavirus B Infection Drug Market Share by Application in 2021 & 2028
    Figure 9. Clinic
    Figure 10. Hospital
    Figure 11. Others
    Figure 12. Global Influenzavirus B Infection Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Influenzavirus B Infection Drug Market Size (2017-2028) & (US$ Million)
    Figure 14. Global Influenzavirus B Infection Drug Sales (2017-2028) & (K Pcs)
    Figure 15. Influenzavirus B Infection Drug Sales Share by Manufacturers in 2021
    Figure 16. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers in 2021
    Figure 17. The Global 5 and 10 Largest Influenzavirus B Infection Drug Players: Market Share by Revenue in 2021
    Figure 18. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 19. Global Influenzavirus B Infection Drug Sales Market Share by Region (2017-2022)
    Figure 20. Global Influenzavirus B Infection Drug Sales Market Share by Region in 2021
    Figure 21. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2017-2022)
    Figure 22. Global Influenzavirus B Infection Drug Revenue Market Share by Region in 2021
    Figure 23. U.S. Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Canada Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. Germany Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. France Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. U.K. Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. Italy Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. Russia Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. China Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. Japan Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. South Korea Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. India Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. Australia Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Taiwan Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Indonesia Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Thailand Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Malaysia Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Philippines Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Vietnam Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Mexico Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Brazil Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. Argentina Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Turkey Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 45. Saudi Arabia Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 46. UAE Influenzavirus B Infection Drug Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 47. Sales Market Share of Influenzavirus B Infection Drug by Type (2017-2022)
    Figure 48. Manufacturing Cost Structure of Influenzavirus B Infection Drug
    Figure 49. Manufacturing Process Analysis of Influenzavirus B Infection Drug
    Figure 50. Influenzavirus B Infection Drug Industrial Chain Analysis
    Figure 51. Channels of Distribution
    Figure 52. Distributors Profiles
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation
    Figure 55. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
GlaxoSmithKline Plc
Green Cross Corp
Inovio Pharmaceuticals Inc
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Park Active Molecules
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
Frequently Asked Questions
Influenzavirus B Infection Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Influenzavirus B Infection Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Influenzavirus B Infection Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports